Author: CannabisNewsWire (CNW)

About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Flora Growth Corp. (NASDAQ: FLGC) Closes the First Half of 2022 with UK Product Launch, Successful Brand Acquisition, and a Collaboration with Ricky Williams’ Cannabis Brand, Highsman

  • Flora’s collaboration with Highsman seeks to elevate both Highsman and Vessel, Flora’s accessories brand, thereby inspiring greatness and creating an experience worth sharing
  • The company’s acquisition of Masaya allows it to deliver on its promise to invest in safe, thorough, and cutting-edge cannabis research
  • Flora’s product launch on Amazon.co.uk marks a big step in operations expansion in Europe

The first half of 2022 has been successful for Flora Growth (NASDAQ: FLGC). At the beginning of the year, the company’s management noted how the cannabis sector was ripe for the picking. They noted how great brands and cost advantages are optimal traits for the company’s long-term market leadership and return on investment (“ROI”), emphasizing the opportunities ahead (https://cnw.fm/MnWUI).

Flora Growth has since partnered with Highsman, a cannabis lifestyle brand built on an appreciation for greatness, founded by former NFL running back Ricky Williams. The collaboration seeks to elevate Highsman and Flora’s cannabis accessories brand, Vessel, (https://cnw.fm/9HXBx)

While announcing the collaboration, James Choe, Flora Growth Chief Strategy Officer (“CSO”) and President of Vessel noted that “Ricky’s story personifies the authenticity and individuality that exists at the core of Vessel, and this collaboration is a true representation of the freedom to be original.”

Following the announcement of the Ricky Williams collaboration, flora announced the acquisition of CBD Brand Masaya. Flora entered into an agreement with Dr. Annabelle Manalo-Morgan, a leading cell biologist, to acquire her brand, along with its patent-pending CBD formulations, which are made up of potent CBD oil and are 100% THC-free (https://cnw.fm/jRF7l).

Upon acquisition, Masaya became an owned Flora brand sold in the United States and the first offering from Flora Life Sciences. It is also projected that the patent-pending formulation, Masaya Pure, will be used in Flora’s current clinical trials with the University of Manchester in the UK. The doctor now serves on Flora’s Board of Directors as the company’s Scientific Advisor. She is also responsible for leading Flora’s global research initiatives, including the ongoing clinical trial on the use of cannabinoids with patients with fibromyalgia.

“We are excited to announce the acquisition of Masaya. The brand’s formulation was developed by Dr. Annabelle for her son and has since been used by thousands of consumers,” noted Luis Merchan, Flora’s Chairman and Chief Executive Officer (“CEO”).

“This acquisition allows us to deliver on our promise to invest in safe, thorough, cutting-edge scientific research that can bring meaningful change via an efficacious and accessible product offering for the people worldwide,” he added.

At the close of May, Flora announced that its wholly-owned subsidiary, JustCBD, would be launching its line of Novel Foods registered CBD products on Amazon.co.uk. Set to launch on the e-commerce store in June 2022, this move would see customers in the UK access JustCBD’s best-selling gummies and tinctures (https://cnw.fm/RIVWM).

This launch marked a significant step in Flora’s operations expansion in Europe. In addition, it showed the company’s commitment to delivering quality cannabis-related products to customers aiming to improve their health and wellness.

“With health and wellness playing an increasingly important role in customers’ lives, we are excited to increase the selection of quality CBD products offered to Amazon customers in the UK,” noted Hussein Rakine, JustCBD’s CEO.

“The JustCBD team looks forward to working closely with Amazon to expand our product offering to other countries as our partnership and brand presence in the United Kingdom grows,” he added.

Going into the second half of the 2022 calendar year, Flora Growth seeks to aggressively pursue the goals set at the beginning of the year, further expanding its market reach and growing its product line and customer numbers.

For more information, visit the company’s website at www.FloraGrowth.com.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Can Marijuana Shield Brain Against Alzheimer’s Disease

With more and more states choosing to legalize cannabis, there has been a significant surge in marijuana research. Several studies have found that cannabis can be effective at alleviating conditions such as inflammation, anxiety disorders and drug addiction. Specifically, marijuana’s possible mental health benefits have drawn in plenty of eager scientists.

Most of this research has involved delta-9 tetrahydrocannabinol (THC), the main psychoactive component in cannabis, and cannabidiol (CBD), a cannabinoid that’s thought to have plenty of medical potential. However, some researchers have been curious whether lesser-known cannabinoids such as cannabinol can have similar health benefits.

Early studies have shown that one cannabinol, CBN, may have neuroprotective properties that allow it to ward off neurodegenerative diseases such as Alzheimer’s and protect brain cells against the ravages of aging. Zhibin Liang, a Glenn Postdoctoral fellow at the Cellular Neurobiology Laboratory and the Paul F. Glenn Center for Biology of Aging Research at Salk Institute for Biological Studies recently discussed cannabis’ potential to treat aging and Alzheimer’s related symptoms.

Speaking at the Being Patient’s LiveTalk series, he said that medical cannabis is an emerging research field, with the bulk of research being done on THC and CBD. He states that his team chose to research CBN’s neuroprotective abilities because they wanted to focus on a minor, nonpsychoactive phytocannabinoid.

Liang and his team targeted the mitochondria in brain cells because they tend to become inefficient as people age and cause oxidative stress in the brain cells. This leads to the accumulation of oxidized proteins in the aging brain cells and can cause neurodegenerative diseases such as Alzheimer’s, Parkinson’s disease, frontotemporal dementia and Huntington’s disease.

The researchers found that cannabinol interacts with mitochondria in the brain cells, helping them maintain their function and effectiveness. This in turn limits mitochondria dysfunction, reduces the levels of oxidative stress in the brain cells and increases the production of adenosine triphosphate (ATP) in brain cells without affecting the CB1 and CB2 receptors in the brain. Low ATP production in the brain cells is associated with increased oxidative stress and is a major factor in the development of neurodegenerative diseases.

This research shows that cannabinol does have the potential to protect the brain against the effects of aging and keep diseases such as Alzheimer’s at bay without any psychoactive effects. Liang’s team is now moving on to preclinical models using mice models of aging and Alzheimer’s to see if they can reproduce CBN’s neuroprotective effects in an animal model.

As more is discovered about the therapeutic potential of this plant, a growing number of people are likely to become interested in growing their own cannabis using some of the latest technologies available such as the Grow Pods being sold by Advanced Container Technologies Inc. (OTC: ACTX) so that end users can be sure that they are consuming medical cannabis of the highest possible quality.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Germany Officially Launches Effort to Legalize Cannabis

Several territories around the world are starting to revise their prohibitionist cannabis policies and are considering legalizing it for either medical and/or recreational use. It’s no surprise as marijuana has been found to have a plethora of medical applications and has generated billions of dollars in taxes so far in a number of countries.

In Europe, German legislators have officially launched efforts to legalize cannabis countrywide and will be holding a series of hearings to help create legislation that can finally end cannabis prohibition in the country. News of cannabis legalization legislation in the country first came late last year when incoming coalition party leaders announced that they had a formal agreement to legalize marijuana and pass comprehensive drug-harm-reduction measures once they assumed power.

The 118-page agreement discussed the introduction of a controlled supply of cannabis for adult consumption as well as cannabis quality control and protecting minors. Earlier this year, the coalition government previewed some of the details of its marijuana legalization plan.

However, the government was forced to turn its attention to the ongoing coronavirus pandemic and put cannabis reform on the back burner. Several months later, leaders of the coalition government are now taking the first steps to put an end to marijuana prohibition and launch a legal, controlled market.

In a recent press release, Commissioner for Addiction and Drug Issues Burkhard Blienert stated that the time to move forward on marijuana legalization has come. Blienert has been working for years to end cannabis criminalization in Germany and says that making this announcement has been especially gratifying.

Officials will begin by holding five hearings with international specialists and experts to debate the minutiae of the policy change and its possible implications. As per the news release, the five hearings will address youth prevention and protection, consumer health and protection, penalties and licensing regulations, supply chains and economic considerations, and international experiences. Blienert notes that officials are especially keen on protecting children and young people from the possible risks associated with passing cannabis legislation.

According to an official FAQ about the cannabis legalization plan, the experiences of other countries that have legalized cannabis will be used to supplement the “specialist knowledge” needed to implement the government’s legalization plan. The FAQ also stated that it still isn’t clear whether the government will include expungements, traffic controls or home cultivations as part of its plan to end criminalization.

Furthermore, the FAQ said that an addiction and drug officer would head the discussions on legalizing cannabis with the aim of presenting a first draft law before the end of the year.

If the biggest economy in Europe legalizes marijuana, there is likely to be a domino effect around the block that could see North American companies such as American Cannabis Partners enter the European market in the coming years.

NOTE TO INVESTORS: The latest news and updates relating to American Cannabis Partners are available in the company’s newsroom at https://cnw.fm/ACP

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Enters Strategic Manufacturing, License Agreements with BevNology

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced the signing of two agreements with Atlanta-based BevNology LLC. According to the update, the first manufacturing operating agreement expands production capabilities for Lexaria’s own growing list of business-to-business (“B2B”) clientele interested in purchasing DehydraTECH-powered active ingredients for consumer packaged-goods brands. A new, state-of-the-art processing facility custom-built by BevNology is operational that increases and broadens production capacity and is currently serving Lexaria’s corporate clients. The second commercial license agreement empowers BevNology to offer DehydraTECH products with active ingredients derived from hemp including cannabidiol (“CBD”) under BevNology and partnered brands. “These agreements build on a long-standing and very successful product development consulting relationship between Lexaria and the expert scientists and personnel at BevNology,” said Chris Bunka, CEO of Lexaria. “BevNology’s formulation and production capabilities are class leading and we are confident that our new relationship with our trusted partner will propel new and exciting growth opportunities for both companies.”

To view the full press release, visit https://cnw.fm/28PAc

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 25 patents granted and over 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Congratulates Colombia’s President-Elect Gustavo Petro

Flora (NASDAQ: FLGC), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, congratulates Gustavo Petro and the Humane Colombia Party on their victory in Sunday’s presidential runoff election in Colombia. “We would like to congratulate President-Elect Gustavo Petro on his victory, and we look forward to working with the new government to continue Colombia’s progressive momentum in the global cannabis industry,” said Luis Merchan, Flora’s chairman and CEO. “We are encouraged by President-Elect Petro’s stance on seeing Colombia become a leader in the legal cannabis industry, and we are hopeful for progressive legislation that will allow Colombia to create a safe environment for cannabis consumption domestically – potentially leading to a recreational market in the country – while also proving Colombia has all the environmental and labor conditions necessary to be a global cannabis powerhouse.”

To view the full press release, visit https://cnw.fm/ZdLIR

About Flora Growth Corp.

Flora is building a connected, design-led collective of plant-based wellness and lifestyle brands delivering the most compelling customer experiences in the world, one community at a time. As the operator of one of the most extensive outdoor cannabis cultivation facilities, Flora leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its commercial, house of brands and life sciences divisions. Visit www.FloraGrowth.com or follow @floragrowthcorp on social media for more information.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Advanced Container Technologies Inc.’s (ACTX) GrowPods Can Help Address Global Lettuce Shortage

Advanced Container Technologies (OTC: ACTX) announced that GrowPods – transportable modular hydroponic farms – can help reduce the global lettuce shortage. The crisis began in 2020 when, according to Growing Produce, California lettuce cultivators faced hotter-than-average temperatures and crop diseases that led to a shortage of iceberg and romaine lettuce. The conditions bled into 2021, with Mintec indicating that lettuce increased in price 67% from the previous year due to low supplies. “Almost all plants grow faster hydroponically than they do in soil-based farming methods,” the publication reported. “This is because the plant’s light, nutrition and water are all under your complete control.” Iceberg lettuce can be harvested in just six to eight weeks, and romaine and butterhead as quickly as three to four weeks. “In general, most hydroponic leafy greens offer 11-13 harvests per year.”

To view the full press release, visit https://cnw.fm/IoELJ

About Advanced Container Technologies Inc.

Advanced Container Technologies is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer(R), that store and grind pharmaceuticals, herbs, teas and other solids or liquids. For more information, visit the company’s website at www.AdvancedContainerTechnologies.com.

NOTE TO INVESTORS: The latest news and updates relating to ACTX are available in the company’s newsroom at https://cnw.fm/ACTX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Expanding Array of API Enhancements Through Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Patented Drug Technology Bodes Well for New Patient Solutions

  • Drug bioavailability enhancement technology developer Lexaria Bioscience is working to increase the number of potential new solutions to unmet medical needs and improving existing treatments for other chronic conditions
  • Lexaria’s patented DehydraTECH solution transforms a wide variety of orally and topically administered products into enhanced solutions that make the active pharmaceutical ingredients (“APIs”) more rapidly available and effective at lower doses 
  • DehydraTECH-enhanced products have also demonstrated the ability to cross the blood-brain barrier through fatty acid transport proteins 
  • The company’s ongoing series of tests of different DehydraTECH-enhanced products has led to a pre-IND filing with the FDA for a prospective registered treatment for hypertension, while other anticipated potential therapies target seizures, nicotine addiction and erectile dysfunction

The COVID pandemic that roiled the world’s healthcare systems during the past two years (and appears to be hospitalizing an increasing number of patients again (https://cnw.fm/iEIXl) revealed a marked demand for repurposing existing drugs for unanticipated treatments, particularly prior to the provisional development of various targeted vaccines to combat the novel coronavirus (https://cnw.fm/cnOfh). 

New data analysis has revealed the potential for several existing biopharma products to be repositioned to treat patients with unmet medical needs, potentially opening the way for dozens of new solutions to chronic medical conditions (https://cnw.fm/QwudW).

At the same time, drug technology innovator Lexaria Bioscience (NASDAQ: LEXX) is finding ways to make available pharmaceuticals and wellness products more effective at doing what they do to treat patient needs, helping to expand the range of potential solutions to chronic health concerns and unmet medical needs.

Lexaria’s patented DehydraTECH product is a technology used to increase the bioavailability of drugs administered orally or transdermally while adding zero chemical byproducts. 

The company’s ongoing testing is delivering data that demonstrates the DehydraTECH-enhanced products’ ability to take effect faster and more potently in placebo-controlled and double-blinded human clinical trials. 

As an example of some of Lexaria’s testing, a series of studies have advanced its investigation of DehydraTECH-CBD from lab animal to human subject stage as a potential treatment for hypertension (heart disease-related high blood pressure) and the company is pursuing a pre-Investigational New Drug (“IND”) meeting with the U.S. Food and Drug Administration (“FDA”) to file its product as a prospective registered treatment this year (https://cnw.fm/sQMAP).

Another series of tests involve the DehydraTECH-nicotine oral pouch. Smoked nicotine is the world’s leading avoidable cause of death, but non-combusted oral nicotine is dramatically less harmful. is being advanced as a non-inhaled but rapidly available Lexaria’s DehydraTECH-nicotine oral pouch is being tested this summer in a human clinical study against existing leading product brands including Zyn (Swedish Match) and ON! (Altria). Lexaria expects its DehyraTECH processed and purified nicotine to work faster than leading brands, delivering higher levels of consumer satisfaction.

Another R&D program is pitting DehydraTECH-CBD against generic CBD and Epidiolex to evaluate DehydraTECH’s ability to improve treatments for epileptic seizures – that testing will be ongoing throughout much of 2022. And if all that isn’t enough, antiviral research shows DehydraTECH enhanced versions of Remdesivir and Ebastine were effective at inhibiting COVID’s SARS- CoV-2 virus and improving their delivery into bloodstream, as well as that of Darunavir and Efavirenz, which are used in treating HIV / AIDS and regarded as potential COVID therapies (https://cnw.fm/I18cp).

With the expanding reach of the company’s research, Lexaria is optimistic its patented technology for delivering APIs into the bloodstream and across the blood-brain barrier with reduced liver metabolization — adaptable to multiple ingestible product formats such as tablets, capsules, oral suspensions and mouth-melts — will prove disruptive to the pharmaceutical industry. 

All planned Lexaria operations are fully funded through Q3 2023 at this time. 

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Climate Change Could Influence How, Where Marijuana Is Grown

Marijuana is rarely on the table whenever discussions of climate change are underway. However, as the world grapples with the effects of decades of greenhouse emissions and runaway climate change, cannabis growers will find that they have to adapt.

It is essentially the same issue that has disrupted agricultural-based industries such as wine: shifting weather patterns coupled with climate change are making regions that have previously the perfect conditions for cultivating inhospitable. In the next couple of years, marijuana growers in the country may have to change where and how they grow cannabis if they wish to remain competitive.

This could include switching to shorter growing cycles to ensure your plants mature and flower before any floods, fires or early freezes strike. It may also involve switching to different strains of cannabis because the planet heats up and makes it difficult for certain strains to flourish.

For instance, a scientific study recently published in “Earth and Space Science” journal revealed that parts of Colorado are experiencing aridification due to changes in stream flows caused by climate change. These regions will lose one-half their snow by 2028 and will look more like Arizona in the coming decades.

Researchers behind the study say that while Colorado isn’t turning into a desert any time soon, they expect to see increasing aridity moving forward. In states that have vibrant hemp and marijuana sectors, this change in climate could affect how cultivators grow the two plant varieties in the future.

Runaway climate change is already starting to affect America’s wine industry. In 2021, an independent organization of journalists and scientists called Climate Central noted that shifts in weather patterns would soon make some wine regions too warm and dry to cultivate certain grape varieties.

The New Jersey-based organization states that growing season temperatures have increased by 2.0°F since 1970, forcing vineyards that produce chardonnay to switch to merlot grapes.

Players in the cannabis sector could be making such choices themselves in the next couple of years. The northeast is experiencing shorter and warmer summers, making it difficult for growers to make predictions for the coming seasons, said director of cultivation Lauren Frontier.

Last July, her cannabis cultivation operation received four times the amount of rain it normally gets in a whole year. She is now considering cannabis strains whose genetics allow them to withstand heavy rain and high humidity.

She is also considering shorter-term genetics such as autoflowers. Cannabis is an extremely adaptable plant that can thrive in any location, Fortier declares. Collaboration between farmers and breeders will help them develop strains and cultivation methods that can withstand shifting weather patterns and climate change so that sector actors such as Cannabis Strategic Ventures Inc. (OTC: NUGS) can continue to meet the needs of their clients without compromising quality or raising prices excessively in a bid to recover the extra costs brought by climate change.

NOTE TO INVESTORS: The latest news and updates relating to Cannabis Strategic Ventures Inc. (OTC: NUGS) are available in the company’s newsroom at http://cnw.fm/NUGS

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Report Says Marijuana Banking, Criminal Expungement Could Be Federally Approved This Year

A new report has revealed that legislators may pass federal cannabis banking reform this year as long as it is combined with existing cannabis expungement legislation. Due to federal prohibition, businesses in the cannabis sector have been unable to access banking and loan services, forcing them to operate on a cash-only basis and limiting their growth opportunity.

The lack of cashless payments has been a particularly touchy issue as it makes it difficult for marijuana businesses to track their finances and keep up with their taxes; it also makes them prime targets for burglaries and robberies.

Politico reported that Senate Majority Leader Chuck Schumer recently met with GOP Representative David Joyce and discussed the possibility of combining his Harnessing Opportunities Act by Pursuing Expungement (HOPE) Act with the SAFE Banking Act. While the SAFE Banking Act would finally grant state-legal cannabis businesses access to banking services, the HOPE Act will provide states with the funds needed to expunge prior-cannabis related offenses from people’s records.

Furthermore, U.S. Cannabis Council president and CEO Steve Hawkins stated earlier this year that the HOPE Act may also contain criminal justice provisions that weren’t included in Representative Ed Perlmutter’s SAFE Banking Act but that appealed to Schumer and other progressive Democrats.

According to Cantor Fitzgerald investment analyst Pablo Zuanic, the reported discussions between Schumer and Joyce are a sign that the Senate majority leader could be open to a “reasonable and realistic” compromise on the SAFE Banking Bill.

Although Schumer has been an avid supporter of comprehensive cannabis reform, he hasn’t been a big fan of the SAFE Banking Act, stating that it seems to protect industry interests first and doesn’t align with his goal of comprehensive cannabis reform. In late 2021, he stated that key senators had agreed not to advance the cannabis banking legislation before federal legalization. The reported talks signal a major change in Schumer’s views on the importance of cannabis banking.

On the other hand, Zuanic isn’t 100% certain that the SAFE Banking Bill will make it into the final version of American competitiveness legislation that is currently being discussed by a bipartisan conference committee. He believes that Joyce’s HOPE Act could be a reasonable compromise for Schumer, who is probably starting to feel the pressure from lawmakers and lobbyists to pass cannabis banking legislation.

Schumer is also expected to officially introduce his Cannabis Administration and Opportunity Act later this month after a couple of delays.

If these regulatory changes are made allowing cannabis banking and other reforms, the industry and its leading players, including Flora Growth Corp. (NASDAQ: FLGC), will check off one hurdle that has bogged down the industry for years.

NOTE TO INVESTORS: The latest news and updates relating to Flora Growth Corp. (NASDAQ: FLGC) are available in the company’s newsroom at https://cnw.fm/FLGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Ground-Breaking Studies Opening ‘Doors Previously Closed to Disruptive New Technology’

Lexaria Bioscience Corp. (NASDAQ: LEXX) understands the shortcomings of orally administered drugs and is developing DehydraTECH(TM), a drug delivery technology that solves challenges such as poor water solubility and membrane permeability, limited absorption and unwanted tastes. “The company began developing DehydraTECH in 2014 and has since strengthened the technology as well as broadened its possible applications… Lexaria has also conducted in vitro and in vivo human and/or animal studies that have evidenced the technology’s ability to mask unwanted tastes, improve the speed of onset, increase bioavailability and brain absorption, and lower dosing – thereby reducing drug administration costs – of APIs,” a recent article reads. “So far, Lexaria has explored how DehydraTECH improves APIs, not limited to, cannabidiol (‘CBD’), oral nicotine and antiviral drugs, with the company describing its oral nicotine investigations as ‘ground-breaking studies to open doors previously closed to disruptive new technology, including the possibility of potent and fast-acting ingestible products that avoid the lung diseases and cancers caused by inhalation of combusted molecules common in smoking.’”

To view the full article, visit https://cnw.fm/SHNT7

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 25 patents granted and over 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.